In recent years, studies have shown that KRT17 is abnormally expressed in a variety of malignant tumours, and up-regulated in lung cancer, pancreatic cancer, gastric cancer and sarcoma (Liu et al., 2018; Chen et al., 2020; Chivu-Economescu et al., 2017; Yan et al., 2020). This evidence concerns the gene KRT17 and familial pancreatic carcinoma.